New intermediate‐stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization

摘要

Abstract Background & Aim The need for a subclassification of Barcelona Clinic Liver Cancer ( BCLC ) intermediate‐stage ( BCLC B) has arisen because of its diversity. We evaluated the prognostic capability of the BCLC B subclassification proposed by Bolondi et?al. in patients treated with transarterial chemoembolization ( TACE ). Furthermore, we introduce a new subclassification for intermediate‐stage hepatocellular carcinoma ( HCC ) by using a new parameter related to tumour burden (up‐to‐11 criteria). Methods Of 3268 patients treated with TACE as first‐line treatment, 821 patients with intermediate‐stage HCC were included in this study. Results According to the Bolondi subclassification, 208 (25.3%), 529 (64.5%), 43 (5.2%) and 41 (5%) patients were in B1, B2, B3 and B4 respectively. The B1, B2 and B3 subclasses in the Bolondi system showed significantly different survival between contiguous stages with median survival of 51.5, 26 and 14.8?months, respectively (both P .001 for B1 vs B2 and B2 vs B3); however, survival was rather worse in B3 than B4 (14.8 vs 25?months, P =.025). According to the newly proposed subclassification, 410 (50%), 364 (44.3%) and 47 (5.7%) patients were in B1, B2 and B3 respectively. The median survival progressively decreased from B1 (44.8 months) to B2 (21.5?months) and B3 (11.3?months), with a significant difference between contiguous stages (both P .001 for B1 vs B2 and B2 vs B3). Conclusions Our new BCLC B substaging system, with up‐to‐11 criteria and Child‐Pugh class as main parameters, has excellent discriminatory power to subclassify TACE ‐treated patients into three prognostic substages.